.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G01A_AntiinfectivesAndAntisepticsExclCombinationsWith.G01AX17_Dapivirine.Dapivirine .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G01A_AntiinfectivesAndAntisepticsExclCombinationsWith.G01AX17_Dapivirine.Dapivirine| name: | Dapivirine |
| ATC code: | G01AX17 | route: | vaginal |
| n-compartments | 1 |
Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used primarily in the form of a vaginal ring to prevent HIV-1 infection in women. The drug is designed for topical use to achieve high local concentrations and minimal systemic exposure. Dapivirine vaginal rings have received a positive scientific opinion from the European Medicines Agency and are recommended by the World Health Organization for HIV prevention in women.
Pharmacokinetic parameters reported for healthy adult women, post-menopausal and reproductive age, enrolled in clinical trials assessing dapivirine vaginal ring (25 mg), steady-state achieved after repeated monthly administration.
Noguchi, LM, et al., & Beigi, RH (2019). Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring. Antimicrobial agents and chemotherapy 63(3) –. DOI:10.1128/AAC.01930-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30602513
Benítez-Gutiérrez, L, et al., & de Mendoza, C (2018). Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert review of clinical pharmacology 11(5) 507–517. DOI:10.1080/17512433.2018.1453805 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29595351
Bunge, KE, et al., & Squires, KE (2020). Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women. Journal of acquired immune deficiency syndromes (1999) 83(2) 135–139. DOI:10.1097/QAI.0000000000002244 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31929401